A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

by Chng, WJ, Lonial, S, Morgan, GJ, Iida, S, Moreau, P, Kumar, SK, Twumasi-Ankrah, P, Villarreal, M, Dash, AB, Vorog, A, Zhang, X, Suryanarayan, K, Labotka, R, Dimopoulos, MA, Rajkumar, SV
Published 2023

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

by Chng, W-J, Goldschmidt, H, Dimopoulos, MA, Moreau, P, Joshua, D, Palumbo, A, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Feng, S, Aggarwal, S, Hajek, R
Published 2022

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

by Moreau, P, Joshua, D, Chng, W-J, Palumbo, A, Goldschmidt, H, Hajek, R, Facon, T, Ludwig, H, Pour, L, Niesvizky, R, Oriol, A, Rosinol, L, Suvorov, A, Gaidano, G, Pika, T, Weisel, K, Goranova-Marinova, V, Gillenwater, HH, Mohamed, N, Aggarwal, S, Feng, S, Dimopoulos, MA
Published 2022

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

by Dimopoulos, M.A., Jakubowiak, A.J., McCarthy, P.L., Orlowski, R.Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K.C., Ramasamy, K., Zweegman, S., Spencer, A., Huang, J.S.Y., Lu, J., Sunami, K., Iida, S., Chng, W.-J., Holstein, S.A., Rocci, A., Skacel, T., Labotka, R., Palumbo, A., Anderson, K.C.
Published 2021